ANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of ...
Please provide your email address to receive an email when new articles are posted on . PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Reenie McCarthy of ...
ANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results